ArticleDEN open2026
Endoscopic Ultrasound-Guided Bile Duct Drainage Enhances Oncological Systemic Therapy Initiation and Capability in Patients With Non-Resectable Malignant Distal Bile Duct Obstructions Compared to Percutaneous Transhepatic Biliary Drainage.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endoscopic retrograde cholangiopancreaticography (ERCP) is the gold standard for bile duct drainage in non-resectable malignant distal bile duct obstruction with jaundice in pancreaticobiliary and duodenal neoplasia. Failed ERCP is either followed by endoscopic ultrasound-guided biliary drainage (EUS-BD) or percutaneous transhepatic biliary drainage (PTBD) as an alternative procedure. This study compares the ability to initiate and continue oncological systemic therapy in patients treated with EUS-BD versus PTBD. Methods: In this retrospective, comparative cohort study, 96 consecutive patients were analyzed. Oncological, demographic, and laboratory parameters were examined, focusing on the capability to initiate chemotherapy and the time interval from intervention to chemotherapy initiation. Results: The EUS-BD group showed a greater reduction in serum bilirubin levels before chemotherapy (2.2 mg/dL vs. 3.9 mg/dL, Conclusion: EUS-BD appears superior to PTBD in facilitating the initiation of oncological systemic therapy, with fewer complications and a shorter time to treatment initiation. Further multicenter studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.